These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 36096284)

  • 1. Multi-Dose Formulation Development for a Quadrivalent Human Papillomavirus Virus-Like Particle-Based Vaccine: Part I - Screening of Preservative Combinations.
    Jerajani K; Wan Y; Kumru OS; Pullagurla SR; Kumar P; Sharma N; Ogun O; Mapari S; Brendle S; Christensen ND; Batwal S; Mahedvi M; Rao H; Dogar V; Chandrasekharan R; Shaligram U; Joshi SB; Volkin DB
    J Pharm Sci; 2023 Feb; 112(2):446-457. PubMed ID: 36096284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-dose Formulation Development for a Quadrivalent Human Papillomavirus Virus-Like Particle-Based Vaccine: Part II- Real-time and Accelerated Stability Studies.
    Sharma N; Jerajani K; Wan Y; Kumru OS; Pullagurla SR; Ogun O; Mapari S; Brendle S; Christensen ND; Batwal S; Mahedvi M; Rao H; Dogar V; Chandrasekharan R; Shaligram U; Volkin DB; Joshi SB
    J Pharm Sci; 2023 Feb; 112(2):458-470. PubMed ID: 36462710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analytical and Preformulation Characterization Studies of Human Papillomavirus Virus-Like Particles to Enable Quadrivalent Multi-Dose Vaccine Formulation Development.
    Jerajani K; Wan Y; Hickey JM; Kumru OS; Sharma N; Pullagurla SR; Ogun O; Mapari S; Whitaker N; Brendle S; Christensen ND; Batwal S; Mahedvi M; Rao H; Dogar V; Chandrasekharan R; Shaligram U; Joshi SB; Volkin DB
    J Pharm Sci; 2022 Nov; 111(11):2983-2997. PubMed ID: 35914546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials.
    Van Damme P; Leroux-Roels G; Simon P; Foidart JM; Donders G; Hoppenbrouwers K; Levin M; Tibaldi F; Poncelet S; Moris P; Dessy F; Giannini SL; Descamps D; Dubin G
    Vaccine; 2014 Jun; 32(29):3694-705. PubMed ID: 24674663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
    Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
    J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine.
    Luxembourg A; Brown D; Bouchard C; Giuliano AR; Iversen OE; Joura EA; Penny ME; Restrepo JA; Romaguera J; Maansson R; Moeller E; Ritter M; Chen J
    Hum Vaccin Immunother; 2015; 11(6):1313-22. PubMed ID: 25912208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylparaben as a preservative in the development of a multi-dose HPV-2 vaccine.
    Miao C; Ma X; Fan J; Shi L; Wei J
    Hum Vaccin Immunother; 2022 Nov; 18(5):2067421. PubMed ID: 35471842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Designing Chimeric Virus-like Particle-based Vaccines for Human Papillomavirus and HIV: Lessons Learned.
    Eto Y; Saubi N; Ferrer P; Joseph J
    AIDS Rev; 2019; 21(4):218-232. PubMed ID: 31834327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IgG and IgM responses to human papillomavirus L1 virus-like particle as a function of dosing schedule and vaccine formulation.
    Park MH; You JW; Kim HJ; Kim HJ
    J Microbiol; 2019 Sep; 57(9):821-827. PubMed ID: 31452045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bacterially expressed human papillomavirus type 6 and 11 bivalent vaccine: Characterization, antigenicity and immunogenicity.
    Pan H; Li Z; Wang J; Song S; Wang D; Wei M; Gu Y; Zhang J; Li S; Xia N
    Vaccine; 2017 May; 35(24):3222-3231. PubMed ID: 28483196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2.
    Tumban E; Muttil P; Escobar CA; Peabody J; Wafula D; Peabody DS; Chackerian B
    Vaccine; 2015 Jun; 33(29):3346-53. PubMed ID: 26003490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Next generation polyphosphazene immunoadjuvant: Synthesis, self-assembly and in vivo potency with human papillomavirus VLPs-based vaccine.
    Marin A; Chowdhury A; Valencia SM; Zacharia A; Kirnbauer R; Roden RBS; Pinto LA; Shoemaker RH; Marshall JD; Andrianov AK
    Nanomedicine; 2021 Apr; 33():102359. PubMed ID: 33476764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial.
    Leung TF; Liu AP; Lim FS; Thollot F; Oh HM; Lee BW; Rombo L; Tan NC; Rouzier R; Friel D; De Muynck B; De Simoni S; Suryakiran P; Hezareh M; Folschweiller N; Thomas F; Struyf F
    Hum Vaccin Immunother; 2015; 11(7):1689-702. PubMed ID: 26062002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of Luminex immunological and competitive Luminex immunological assays for clinical immunogenicity assessment of a 14-valent recombinant human papillomavirus vaccine.
    Zhang X; Meng D; Li H; Li X; Li J; Hu P; Zhao L; Wang R; Zhao C; Luo C; Gu W; Gai W; Wang Y; Xie L
    J Med Virol; 2023 Aug; 95(8):e29050. PubMed ID: 37635425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural Characterization and Formulation Development of a Trivalent Equine Encephalitis Virus-Like Particle Vaccine Candidate.
    Toprani VM; Cheng Y; Wahome N; Khasa H; Kueltzo LA; Schwartz RM; Middaugh CR; Joshi SB; Volkin DB
    J Pharm Sci; 2018 Oct; 107(10):2544-2558. PubMed ID: 29883665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a human papillomavirus type 6/11 vaccine candidate for the prevention of condyloma acuminatum.
    Yu Y; Guo J; Li D; Liu Y; Yu Y; Wang L
    Vaccine; 2018 Aug; 36(32 Pt B):4927-4934. PubMed ID: 30037483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered antigenicity and immunogenicity of human papillomavirus virus-like particles in the presence of thimerosal.
    Chen S; Huang X; Li Y; Wang X; Pan H; Lin Z; Zheng Q; Li S; Zhang J; Xia N; Zhao Q
    Eur J Pharm Biopharm; 2019 Aug; 141():221-231. PubMed ID: 31154067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunoaffinity extraction using conformation-dependent antibodies coupled to SE-HPLC for the development of stability and potency-indicating assay for quadrivalent human papillomavirus vaccine.
    Mostafa MM; Al-Ghobashy MA; Fathalla FA; Salem MY
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Oct; 1032():211-217. PubMed ID: 27037127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Quantitative analysis of nine types of virus-like particles in human papilloma virus bulk by size-exclusion chromatography].
    Long Z; Li X; Li X; Liu J; Nie J; Li C; Li Y; Huang T; Huang W
    Se Pu; 2021 Apr; 39(4):424-429. PubMed ID: 34227763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.
    Olsson SE; Villa LL; Costa RL; Petta CA; Andrade RP; Malm C; Iversen OE; Høye J; Steinwall M; Riis-Johannessen G; Andersson-Ellstrom A; Elfgren K; von Krogh G; Lehtinen M; Paavonen J; Tamms GM; Giacoletti K; Lupinacci L; Esser MT; Vuocolo SC; Saah AJ; Barr E
    Vaccine; 2007 Jun; 25(26):4931-9. PubMed ID: 17499406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.